The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.

Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline).

An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (Abilify Prolonged Release Aqueous Suspension), whether or not it is considered causally related to the Medicinal Product.

Collecting any Situations related to the use of an Otsuka product which may or may not be associated with an adverse event:

• Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure;
• Exposure during breastfeeding;
• Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products);
• Medication errors (e.g. patient took wrong dose);
• Lack of therapeutic efficacy (e.g. the product doesn't work);
• Occupational exposure (e.g.: nurse administering the product is exposed);
• Cases of suspected transmission of infectious agents;
• Use of suspected or confirmed falsified product(s) or quality defect of the product(s);
• Withdrawal reactions;
• Accidental exposure (e.g.: child takes parent's product);
• Drug-drug/drug-food interactions;
• Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population);
• Disease progression/exacerbation of existing disease

(Safety Information)

Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.

(Safety Information)

Collecting the number of patients who recurrence/relapse of Mood Episodes (Efficacy Information)